A Biopharmaceutical Company
About Us
STANJON BioTech is an innovative biopharmaceutical company focused on efficiently acquiring, developing, and commercializing promising new products in the healthcare industry.
The company is a startup founded in 2023 with two core business areas: the first being new product development serving a variety of clinical specialties and the second focusing on research and development of new therapeutics in orthopedic and neurological care. Our model for success is driven by our desire to partner with other industry leaders in collaboration to further expand our company’s portfolio of product offerings.
Business Strategy
Our business strategy is designed for maximum flexibility, allowing us to develop a broad array of new technologies with clinical and commercial potential.
Through our approach, we are creating a portfolio of marketed products and developmental-stage assets that we believe will provide us and our shareholders with a diversified long-term revenue stream, in addition to serving the needs of the patient populations who require the products and treatments in these areas of care.
Business Model
Our model is driven by a talented team of professionals with diverse industry backgrounds focused on leveraging our significant clinical and biotech expertise to expand our portfolio of product opportunities further. We are also collaborating with several renowned academic research institutions including other pharmaceutical companies to serve the needs of our clients better and maximize each opportunity to its fullest potential.​